FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Inderjit Mehmi

Research Profile

Disorders

Physiology

Chemicals & Drugs

Anatomy

Co-author Network

Publications

TOP 3
Javier A Menendez; Inderjit Mehmi; Ruth Lupu
Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Javier A Menendez; Inderjit Mehmi; Ruth Lupu
Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
Javier A Menendez; Luciano Vellon; Inderjit Mehmi; Poh K Teng; David W Griggs; Ruth Lupu
A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Inderjit Mehmi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Javier A Menendez; Inderjit Mehmi; Ruth Lupu
Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(23):3735-46.
2005: Javier A Menendez; Inderjit Mehmi; Ruth Lupu
Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
International journal of oncology 2005;26(3):649-59.
2005: Javier A Menendez; Luciano Vellon; Inderjit Mehmi; Poh K Teng; David W Griggs; Ruth Lupu
A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
Oncogene 2005;24(5):761-79.
2004: Javier A Menendez; Inderjit Mehmi; Vishal A Verma; Poh K Teng; Ruth Lupu
Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
Molecular carcinogenesis 2004;41(3):164-78.
2004: Javier A Menendez; Luciano Vellon; Inderjit Mehmi; Bharvi Praful Oza; Santiago Ropero; ramon colomer; Ruth Lupu
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(29):10715-20.
2004: Javier A Menendez; Bharvi Praful Oza; Ella Atlas; Vishal A Verma; Inderjit Mehmi; Ruth Lupu
Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Oncogene 2004;23(28):4945-58.
2004: Javier A Menendez; Santiago Ropero; Inderjit Mehmi; Ella Atlas; ramon colomer; Ruth Lupu
Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
International journal of oncology 2004;24(6):1369-83.
2004: Javier A Menendez; Inderjit Mehmi; Ella Atlas; ramon colomer; Ruth Lupu
Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
International journal of oncology 2004;24(3):591-608.
2003: Ruth Lupu; Inderjit Mehmi; Ella Atlas; Miaw-Sheue Tsai; Emily Pisha; Hellen Oketch-Rabah; Paiboon Nuntanakorn; Edward J Kennelly; Fredi Kronenberg
Black cohosh, a menopausal remedy, does not have estrogenic activity and does not promote breast cancer cell growth.
International journal of oncology 2003;23(5):1407-12.
2003: J A Menéndez; Inderjit Mehmi; D W Griggs; Ruth Lupu
The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives.
Endocrine-related cancer 2003;10(2):141-52.
2003: Ella Atlas; Kozystof Bojanowski; Inderjit Mehmi; Ruth Lupu
A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity.
Oncogene 2003;22(22):3441-51.
2003: Miaw-Sheue Tsai; Lisa A Shamon-Taylor; Inderjit Mehmi; Careen K Tang; Ruth Lupu
Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer.
Oncogene 2003;22(5):761-8.
2003: Ella Atlas; Marina Cardillo; Inderjit Mehmi; Hengameh Zahedkargaran; Careen Tang; Ruth Lupu
Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.
Molecular cancer research : MCR 2003;1(3):165-75.
2002: Miaw-Sheue Tsai; Daphne F Bogart; Patricia Li; Inderjit Mehmi; Ruth Lupu
Expression and regulation of Cyr61 in human breast cancer cell lines.
Oncogene 2002;21(6):964-73.